Case-Control Study of Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Hospitalizations in Older Adults, United States, 2010-2011

Clinical Infectious Diseases

Volumn 63, Issue 10, 2016, Pages 1304-1311

  Havers, Fiona ^a   Sokolow, Leslie ^a,b   Shay, David K ^a   Farley, Monica M ^c,d   Monroe, Maya ^e   Meek, James ^f   Daily Kirley, Pam ^g   Bennett, Nancy M ^h   Morin, Craig ^j   Aragon, Deborah ^k   Thomas, Ann ^l   Schaffner, William ^m   Zansky, Shelley M ⁱ   Baumbach, Joan ⁿ   Ferdinands, Jill ^a   Fry, Alicia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^f YALE UNIVERSITY   (United States)

^g California Emerging Infections Program   (United States)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

ⁱ NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^j MINNESOTA DEPARTMENT OF HEALTH   (United States)

^k Air Pollution Control Division   (United States)

^l OREGON PUBLIC HEALTH DIVISION   (United States)

^m VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NEW MEXICO DEPARTMENT OF HEALTH   (United States)

more..

Author keywords

influenza vaccination; influenza vaccine effectiveness; influenza associated hospitalization; older adults

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL STATUS; HISPANIC; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCOME; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA VACCINATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELF REPORT; SMOKING; SOCIAL STATUS; UNITED STATES; IMMUNIZATION; INFLUENZA, HUMAN; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES;

EID: 84994408725     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw512     Document Type: Article

References (53)

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PloS One 2015; 10: e0118369.
2. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015; 64:818-25.
3. Bridges CB, Winquist AG, Fukuda K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-38; quiz CE31-37.
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44.
5. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398-405.
6. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178:527-33.
7. Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant 2013; 13:1026-33.
8. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658-66.
9. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35:337-44.
10. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006; 35:345-52.
11. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine 2010; 28:7267-72.
12. Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med 2012; 172:484-91.
13. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373-81.
14. Chen Q, Griffin MR, Nian H, et al. Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged ≥50 years. J Infect Dis 2015; 211:1045-50.
15. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55:951-9.
16. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of testnegative design case-control studies. Lancet Infect Dis 2014; 14:1228-39.
17. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Griffin MR. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis 2013; 56:1774-7.
18. Gilca R, Skowronski DM, Douville-Fradet M, et al. Mid-season estimates of influenza vaccine effectiveness against influenza A(H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PloS One 2015; 10:e0132195.
19. Dawood FS, Prapasiri P, Areerat P, et al. Effectiveness of the 2010 and 2011 Southern Hemisphere trivalent inactivated influenza vaccines against hospitalization with influenza-associated acute respiratory infection among Thai adults aged /=50 years. Influenza Other Respir Viruses 2014; 8:463-8.
20. Cheng AC, Holmes M, Irving LB, et al. Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010-11 seasons: a test-negative observational study. PloS One 2013; 8:e68760.
21. Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011; 203:500-8.
22. Kwong JC, Campitelli MA, Gubbay JB, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis 2013; 57:820-7.
23. Castilla J, Godoy P, Dominguez A, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis 2013; 57:167-75.
24. Puig-Barbera J, Diez-Domingo J, Arnedo-Pena A, et al. Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. Vaccine 2012; 30:5714-20.
25. Chaves SS, Lynfield R, Lindegren ML, Bresee J, Finelli L. The US Influenza Hospitalization Surveillance Network. Emerg Infect Dis 2015; 21:1543-50.
26. Cheak-Zamora NC, Wyrwich KW, McBride TD. Reliability and validity of the SF-12v2 in the Medical Expenditure Panel Survey. Qual Life Res 2009; 18:727-35.
27. deLeeuw J. Introduction to Akaike (1973) information theory and an extension of the maximum likelihood principle. In: Kotz S, Johnson NL. eds. Breakthroughs in statistics. Vol 1. London: Springer-Verlag, 1992:599-609.
28. Kissling E, Valenciano M, Cohen JM, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 2011; 6:e27622.
29. Skowronski DM, Janjua NZ, De Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332-42.
30. Pebody RG, Andrews N, Fleming DM, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect 2013; 141:620-30.
31. Choi WS, Noh JY, Seo YB, et al. Case-control study of the effectiveness of the 2010-2011 seasonal influenza vaccine for prevention of laboratory-confirmed influenza virus infection in the Korean adult population. Clin Vaccine Immunol 2013; 20:877-81.
32. Jimenez-Jorge S, Savulescu C, Pozo F, et al. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012; 30:3595-602.
33. Martinez-Baz I, Martinez-Artola V, Reina G, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study. BMC Public Health 2013; 13:191.
34. Englund H, Campe H, Hautmann W. Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season. Epidemiol Infect 2013; 141:1807-15.
35. Castilla J, Martinez-Artola V, Salcedo E, et al. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. Vaccine 2012; 30:195-200.
36. McNeil S, Shinde V, Andrew M, et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. Euro Surveill 2014; 19: pii:20729.
37. Cheng AC, Brown S, Waterer G, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2012: the Influenza Complications Alert Network (FluCAN). Commun Dis Intell Q Rep 2013; 37: E246-52.
38. McNeil SA, Andrew MK, Ye L, et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill 2015; 20:21024.
39. Turner N, Pierse N, Bissielo A, et al. The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. Vaccine 2014; 32:3687-93.
40. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
41. Orenstein EW, De Serres G, Haber MJ, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007; 36:623-31.
42. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
43. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013; 18:pii:20585.
44. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.
45. Ferdinands JM, Olsho LE, Agan AA, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 2014; 210:674-83.
46. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159-67.
47. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-36.
48. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62.
49. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69.
50. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-56.
51. Yao X, Hamilton RG,Weng NP, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 2011; 29:5015-21.
52. Centers for Disease Control and Prevention. Update: influenza activity-United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. MMWR Morb Mortal Wkly Rep 2011; 60:705-12.
53. McIntyre AF, Gonzalez-Feliciano AG, Bryan LN, et al. Seasonal influenza vaccination coverage-United States, 2009-10 and 2010-11. Morb Mortal Wkly Rep Surveill Summ 2013; 62(suppl 3):65-8.